Prevalence and Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus (hVISA) Among Clinical Isolates: A Comparative Evaluation of Screening Methods

临床分离株中异质性耐万古霉素中介金黄色葡萄球菌(hVISA)的流行率和检测:筛查方法的比较评价

阅读:1

Abstract

BACKGROUND:  Staphylococcus aureus is a major human pathogen, with methicillin-resistant S. aureus (MRSA) posing a significant challenge due to its resistance to multiple antibiotics. Vancomycin remains the drug of choice for MRSA infections; however, resistance mechanisms such as vancomycin-intermediate S. aureus (VISA) and heteroresistant VISA (hVISA) have emerged, leading to treatment failures. This study aimed to determine the prevalence of hVISA among clinical isolates and compare the efficacy of different screening methods. METHODS:  A prospective, observational study was conducted over 1.5 years, analyzing 102 non-duplicate clinical isolates of S. aureus from various specimens. Identification and antimicrobial susceptibility testing were performed using standard microbiological methods. MRSA detection was done using cefoxitin disc diffusion, while vancomycin susceptibility was assessed using minimum inhibitory concentration (MIC) determination. hVISA screening was performed using four methods: brain heart infusion agar with 4 µg/mL vancomycin (BHIV4), gradient plate method (GPM), macro E-test (MET), and E-test GRD, as these methods have been shown to be more effective than other screening techniques in previous studies. The PAP-AUC ratio was used as the gold standard for hVISA confirmation. RESULTS:  Among the 102 isolates, 49.02% were MRSA, and all were susceptible to vancomycin based on MIC values. However, 8.82% exhibited the hVISA phenotype out of the total S. aureus (102) isolates. hVISA was more prevalent in hospital-acquired infections (100% of hVISA isolates) than in community-acquired cases. The BHIV4 method showed the highest sensitivity (88.89%), while the gradient plate method had the highest specificity (94.62%). CONCLUSION:  The detection of hVISA is critical for optimizing treatment strategies and preventing therapeutic failures. The study suggests that BHIV4 screening can serve as an effective method for initial hVISA detection. Continuous surveillance and judicious antimicrobial use are essential to curb the emergence of resistance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。